Key Highlights
•
A new study found that microglial reactivity, a sign of brain inflammation, predicts shrinkage of the hippocampus, a key memory area, in patients with cerebral small vessel disease. This suggests that inflammation may be a key driver of brain damage in this common cause of vascular dementia, linking vascular problems with neurodegenerative processes.
Source →
•
A comprehensive review concludes that while liver stiffness measurement is strongly linked to the risk of liver failure in patients with advanced liver disease, current non-invasive blood tests are only modestly effective at predicting this outcome. This highlights a critical need for better predictive tools, potentially using artificial intelligence or new biomarkers, to personalize care and prevent serious complications.
Source →
•
A new antibody-drug conjugate, datopotamab deruxtecan, was tested in a major international trial for patients with previously untreated, advanced triple-negative breast cancer, a type with very limited treatment options. This represents a significant potential new therapy for a patient group that has a poor prognosis and few effective treatments available, especially if they cannot receive immunotherapy.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
